Longboard Pharmaceuticals



HBM contact: Dr Ivo Staijen, Dr Chandra P. Leo

Company status: public

Longboard Pharmaceuticals aims to deliver novel, transformational medicines to patients with rare neurological diseases, including developmental and epileptic encephalopathies. Longboard's compounds were discovered and evolved out of the validated world-class GPCR research engine of Arena Pharmaceuticals.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171